biostudies-literaturePapadakis VAssociation Hubert Gouin-Enfance et CancerFrench Society of Pediatric OncologyEuropean Union's Seventh Framework Programmethe Fédération Enfant & SantéEuropean Union's Seventh Framework ProgrammeFondazione Italiana per la Lotta al NeuroblastomaInstitute of Health Carlos III-General Subdirectorate for Evaluation and Promotion of Research4007https://www.ebi.ac.uk/biostudies/studies/S-EPMC9406882biostudies-literatureUnknown14(16)Background: To assess whether expectant observation of infants ≤ 90 days old with small suprarenal masses (sSRMs) could avoid unnecessary surgery without impacting outcome. Methods: Infants ≤ 90 days with a ≤ 5 cm mass, without midline extension or lymph node or distant spread were registered (ClinicalTrials.org:NCT01728155). Once staging was completed, they were followed with ultrasound, MRI and urinary catecholamines. Surgical resection was only planned if there was a ≥40% mass volume increase or for a mass persisting after 48 weeks of the planned observation. Results: Over a 5-year period, 128 infants were registered. No infant had detectable MYCN amplification in the peripheral blood. Surgery was performed in 39 (30.5%) patients, in 18 during and in 21 after the plCancersSuprarenal Masses in Very Young Infants: Is It Safe to Watch and Wait? Report of a SIOPEN Observational Study Results.PMC9406882PT13/0002/0032 and PT17/0017/0035ItalyENCCA_261474FranceAsh SSarnacki SCanete ASchleiermacher GSegura VBrichard BGranata CPlantaz DConte MDi Cataldo APapadakis VCombaret VBermudez JDLadenstein RWheeler KFagnani AMfalseSuprarenal Masses in Very Young Infants: Is It Safe to Watch and Wait? Report of a SIOPEN Observational Study Results.Background: To assess whether expectant observation of infants ≤ 90 days old with small suprarenal masses (sSRMs) could avoid unnecessary surgery without impacting outcome. Methods: Infants ≤ 90 days with a ≤ 5 cm mass, without midline extension or lymph node or distant spread were registered (ClinicalTrials.org:NCT01728155). Once staging was completed, they were followed with ultrasound, MRI and urinary catecholamines. Surgical resection was only planned if there was a ≥40% mass volume increase or for a mass persisting after 48 weeks of the planned observation. Results: Over a 5-year period, 128 infants were registered. No infant had detectable MYCN amplification in the peripheral blood. Surgery was performed in 39 (30.5%) patients, in 18 during and in 21 after the pl2022-01-01T00:00:00Z2022 Aug2026-06-20T03:14:25.466Z2024-10-16T04:12:06.004ZS-EPMC94068823601100510.3390/cancers14164007